SCHEMBL6356259

SCHEMBL6356259

CCc1cc(CCc2nnnn2Cc2ccccc2)c(OC)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TSHR P16473 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HSD17B10 Q99714 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 3/20 0.40
GLA P06280 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HTT P42858 1/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DAGLA Q9Y4D2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355835 0.90 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL6359711 0.90 ALDH1A1 (0.51) ALDH1A1TSHRSMN1; SMN2LMNAHPGD
SCHEMBL6355368 0.80 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL4407027 0.75 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL156417 0.75 ALDH1A1 (0.66) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL4411061 0.73 ALDH1A1 (0.59) ALDH1A1KMT2AMEN1LMNADAGLA
SCHEMBL4407461 0.72 ALDH1A1 (0.58) ALDH1A1KMT2AMEN1LMNADAGLA
SCHEMBL2091467 0.71 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL4407098 0.71 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL6356262 0.70 TSHR (0.47) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 ALDH1A1 1194/4885KMT2A 1711/4885MEN1 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.